

**IN THE CLAIMS**

1-19. (Canceled)

20. (Previously presented) A method of testing a compound for biological activity, which method comprises:

- (i) providing cells expressing one of the CD94/NKG2 family of receptors at the cell surface;
- (ii) contacting the cells with HLA-E in the presence of the test compound; and
- (iii) determining whether the presence of the compound affects the binding of HLA-E to the cells.

21. (Previously presented) The method according to claim 20, wherein the CD94/NKG2 receptors are inhibitory NK cell receptors.

22. (Previously presented) The method according to claim 20, wherein the CD94/NKG2 receptors are stimulatory NK cell receptors.

23. (Previously presented) Compounds identified by the method according to claim 20, as affecting the binding of HLA-E to CD94/NKG2 receptors.

24 -29. (Canceled)

30. (Original) The method according to claim 21, wherein the inhibitory CD94/NKG2 receptors are CD94/NKG2A receptors.

31. (Original) The method according to claim 22, wherein the stimulatory CD94/NKG2 receptors are CD94/NKG2C receptors.

32. (New) A method of testing a compound for biological activity, which method comprises:

- (i) providing cells expressing a CD94/NKG2 receptor, wherein the NKG2 member is selected from the group consisting of NKG2A, NKG2B, NKG2C, NKG2D, NKG2E, and NKG2F at the cell surface;
- (ii) contacting the cells with HLA-E in the presence of the test compound; and
- (iii) determining whether the presence of the compound affects the binding of HLA-E to the cells.

33. (New) The method according to claim 32, wherein the CD94/NKG2 receptor is an inhibitory NK cell receptor.

34. (New) The method according to claim 32, wherein the CD94/NKG2 receptor is a stimulatory NK cell receptor.

**Applicant:** Braud et al.  
**Application No.:** 09/555,555

35. Compounds identified by the method according to claim 32, as affecting the binding of HLA-E to CD94/NKG2 receptors.

36. (New) The method according to claim 33, wherein the inhibitory CD94/NKG2 receptor is a CD94/NKG2A receptor.

37. (New) The method according to claim 32, wherein the stimulatory CD94/NKG2 receptor is a CD94/NKG2C receptor.